{"id":915648,"date":"2025-12-03T09:47:54","date_gmt":"2025-12-03T14:47:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/"},"modified":"2025-12-03T09:47:54","modified_gmt":"2025-12-03T14:47:54","slug":"bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/","title":{"rendered":"bioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable"},"content":{"rendered":"

<\/p>\n

bioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable<\/b><\/p>\n

SAN ANTONIO, Texas–(BUSINESS WIRE<\/a>)–bioAffinity Technologies, Inc.<\/b><\/a> (Nasdaq: BIAF; BIAFW)<\/b>,a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer Gordon Downie, MD, PhD, will present a poster at the American Cancer Society National Lung Cancer Roundtable<\/a> (NLCRT) showcasing three cases in which CyPath\u00ae Lung, a noninvasive sputum-based flow cytometry test, successfully identified Stage 1A lung cancer in patients with atypical and diagnostically challenging presentations.\n<\/p>\n

\n\u201cIndeterminate pulmonary nodules pose a significant and growing clinical burden, especially when clinicians are confronted with conflicting or inconclusive diagnostic data,\u201d Dr. Downie said. \u201cRisk calculators, imaging, genetic testing, and biomarker tools can at times point in opposing directions, leaving clinicians and patients uncertain about next steps. This challenge is amplified in patients with unusual risk profiles, discordant imaging and advanced age.\u201d\n<\/p>\n

\nDr. Downie\u2019s poster, \u201cCyPath\u00ae Lung in Practice: From Uncertainty to Clarity and Confidence,\u201d<\/i> details three complex cases from his tenure as Director of the Titus Regional Hospital Lung Nodule Clinic and Interventional Pulmonology. CyPath\u00ae Lung was used alongside other diagnostic tools, including standard low-dose CT (LDCT), PET imaging, risk calculators, bronchoscopy and blood serum marker tests. In each case, CyPath\u00ae Lung provided clarity and actionable results which led to confirmed diagnoses at the earliest and most treatable stage.\n<\/p>\n

\n\u201cThese three cases illustrate scenarios that are increasingly common in real-world lung nodule practice,\u201d Dr. Downie said. \u201cIncorporating CyPath\u00ae Lung into the diagnostic pathway can accelerate diagnosis, guide difficult conversations with anxious patients, and prevent unnecessary invasive procedures that carry their own risks.\u201d\n<\/p>\n

\nThe NLCRT is a coalition of 194 medical, public health, advocacy, government, and corporate organizations that work together to fight lung cancer by working collectively and collaboratively to reduce lung cancer mortality. This year\u2019s annual meeting is December 8-9, 2025, at the Grand Hyatt Atlanta in Buckhead, Atlanta, Georgia.\n<\/p>\n

\nDr. Downie\u2019s poster session is scheduled for Monday, December 8, 2025, from 2:35-3:15 p.m. ET. The poster<\/a> can be viewed on the bioAffinity website.\n<\/p>\n

About CyPath\u00ae Lung<\/b><\/p>\n

\nCyPath\u00ae Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath\u00ae Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results<\/a> demonstrated that CyPath\u00ae Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit www.cypathlung.com<\/a>.\n<\/p>\n

About bioAffinity Technologies, Inc.<\/b><\/p>\n

\nbioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company\u2019s first product, CyPath\u00ae Lung<\/a>, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath\u00ae Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services<\/a>, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com<\/a>.\n<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nCertain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of CyPath\u00ae Lung to identify lung cancer and the other factors discussed in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20251203174022\/en\/<\/a><\/span><\/p>\n

\nbioAffinity Technologies
\n
Julie Anne Overton
\n
Director of Communications
\n
jao@bioaffinitytech.com<\/a><\/p>\n

KEYWORDS:<\/b> Texas United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Medical Devices Hospitals Health Technology Biotechnology Other Health Radiology Health General Health Oncology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

bioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable SAN ANTONIO, Texas–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer Gordon Downie, MD, PhD, will present a poster at the American Cancer Society National Lung Cancer Roundtable (NLCRT) showcasing three cases in which CyPath\u00ae Lung, a noninvasive sputum-based flow cytometry test, successfully identified Stage 1A lung cancer in patients with atypical and diagnostically challenging presentations. \u201cIndeterminate pulmonary nodules pose a significant and growing clinical burden, especially when clinicians are confronted with conflicting or inconclusive diagnostic data,\u201d Dr. Downie said. \u201cRisk calculators, imaging, genetic testing, and biomarker … <\/p>\n

Continue reading “bioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-915648","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nbioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"bioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"bioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable SAN ANTONIO, Texas–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer Gordon Downie, MD, PhD, will present a poster at the American Cancer Society National Lung Cancer Roundtable (NLCRT) showcasing three cases in which CyPath\u00ae Lung, a noninvasive sputum-based flow cytometry test, successfully identified Stage 1A lung cancer in patients with atypical and diagnostically challenging presentations. \u201cIndeterminate pulmonary nodules pose a significant and growing clinical burden, especially when clinicians are confronted with conflicting or inconclusive diagnostic data,\u201d Dr. Downie said. \u201cRisk calculators, imaging, genetic testing, and biomarker … Continue reading "bioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-03T14:47:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251203174022r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"bioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable\",\"datePublished\":\"2025-12-03T14:47:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\\\/\"},\"wordCount\":846,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251203174022r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\\\/\",\"name\":\"bioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251203174022r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-12-03T14:47:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251203174022r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20251203174022r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"bioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"bioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/","og_locale":"en_US","og_type":"article","og_title":"bioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable - Market Newsdesk","og_description":"bioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable SAN ANTONIO, Texas–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced that Chief Medical Officer Gordon Downie, MD, PhD, will present a poster at the American Cancer Society National Lung Cancer Roundtable (NLCRT) showcasing three cases in which CyPath\u00ae Lung, a noninvasive sputum-based flow cytometry test, successfully identified Stage 1A lung cancer in patients with atypical and diagnostically challenging presentations. \u201cIndeterminate pulmonary nodules pose a significant and growing clinical burden, especially when clinicians are confronted with conflicting or inconclusive diagnostic data,\u201d Dr. Downie said. \u201cRisk calculators, imaging, genetic testing, and biomarker … Continue reading \"bioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-03T14:47:54+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251203174022r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"bioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable","datePublished":"2025-12-03T14:47:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/"},"wordCount":846,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251203174022r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/","name":"bioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251203174022r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-12-03T14:47:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251203174022r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20251203174022r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-noninvasive-cypath-lung-test-to-be-highlighted-at-american-cancer-society-national-lung-cancer-roundtable\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"bioAffinity Technologies\u2019 Noninvasive CyPath\u00ae Lung Test to Be Highlighted at American Cancer Society National Lung Cancer Roundtable"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915648","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=915648"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/915648\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=915648"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=915648"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=915648"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}